Published : 12 Mar 2024
Aagami has won a New Client from Alabama, USA. The client is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases.
With a rich pipeline, the client’s lead program has completed Phase 2b Clinical Trial on Atopic Dermatitis.
They are looking for Aagami support for strategic partnering and investments. Aagami is committed to strive for bringing success.
If you would like to evaluate this opportunity for investment/partnering considerations, please contact us.